ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
38 announcements
ICRA Limited has reaffirmed the credit rating of Zensar Technologies for its long-term and short-term fund/non-fund based bank facilities, totaling ₹191 Crore.
Designated person Vijayasimha Alilughatta acquired 8,983 shares of Zensar Technologies through an ESOP exercise. The transaction is valued at ₹0.43 Crore.
Zensar Technologies has allotted 25,691 equity shares to employees following the exercise of their vested ESOPs.
Zensar Technologies Ltd has filed its quarterly shareholding pattern for the period ended December 31, 2025, in compliance with regulatory requirements.
Zensar Technologies announced the completed merger of its US subsidiaries M3BI LLC and Bridgeview Life Sciences LLC into Zensar Technologies Inc. The mergers become effective September 1, 2026.
Zensar Technologies Limited has received an independent ESG score of 74 from Crisil ESG Ratings & Analytics Limited, categorizing the company under 'Leadership' for FY2026.
Zensar whitepaper outlining South Africa's financial services trends for 2026, focusing on payments-led commerce, AI adoption, and regulatory shifts.
Shareholders approved resolutions at Zensar Technologies' AGM, including a Rs. 750 Crore related party transaction with its South African subsidiary.
Zensar Technologies Limited concluded its 63rd Annual General Meeting on July 30, 2026. The meeting covered financial statements, dividend declaration, and related party transaction approvals.
Zensar Technologies has received in-principle board approval to merge its US-based step-down subsidiaries, Bridgeview Life Sciences LLC and M3BI LLC, into Zensar Technologies Inc.
Zensar Technologies reported Q1FY27 consolidated revenue of $159.5 million, reflecting 1.1% sequential constant-currency growth. The update highlights ongoing AI-led business transformation and strategic operational performance.
Zensar Technologies Ltd reported revenue from operations of ₹1,508 Cr (+8.9% YoY) and net profit of ₹183.8 Cr (+1.0% YoY) for Q1 FY27.
Zensar Technologies has filed a revised Integrated Annual Report for FY 2025-26 to correct an issue with the RPG Group logo in the document.
Zensar Technologies Limited has scheduled a board meeting on July 29, 2026, to consider and approve the unaudited standalone and consolidated financial results for Q1 FY2026-27.
Zensar Technologies has granted 6,28,502 stock options to eligible employees under the 'ESOP 2025' scheme. These options have an exercise price of ₹2 per option.
Zensar Technologies will hold its AGM on July 30, 2026, to approve FY26 financials and declare a final dividend of ₹12.60/share. It also seeks approval for ₹750 Cr related-party transactions with its South Africa subsidiary.
Zensar Technologies filed its BRSR for FY2025-26, detailing operations and subsidiaries. The report includes employee data and CSR metrics but no financial results or corporate action.
Zensar Technologies filed its Integrated Annual Report for FY2025-26. The report covers corporate overview, strategy, governance, and financial statements for shareholder review.
Zensar Technologies has issued a notice for its 63rd AGM on July 30, 2026. The agenda includes adopting financial statements and declaring a final dividend of INR 12.60 per share.
Zensar Technologies scheduled its 63rd AGM for July 30, 2026. The record date for the final dividend is July 17, 2026.
Zensar Technologies allotted 38,238 equity shares to employees upon ESOP exercise. This increases the company's issued share capital to Rs. 455,067,784.
Zensar Technologies appointed Mr. Brahma Pandey as Senior Vice President effective June 15, 2026. This strengthens the company's senior management team.
Zensar reported FY26 revenue of $643.7M (+3.1% YoY) with a PAT margin of 13.5%. The company is pivoting toward an 'AI-Native' strategy for FY27 growth.
Zensar Technologies Limited approved the allotment of 1,200 equity shares of Rs. 2/- each to employees upon the exercise of ESOPs. Consequently, the company's issued and subscribed share capital has increased to Rs. 45.50 Crore.
Zensar Technologies Limited has granted 15,678 stock options to eligible employees under its ESOP 2025 scheme. The options carry an exercise price of Rs. 2 per share, equal to the face value. This grant aims to align employee interests with company performance and provides a five-year exercise window post-vesting.
Zensar whitepaper outlining 2026 UK Financial Services trends. Highlights shift to Open Finance, AI-driven banking, and ESG growth amid tighter regulation.
Zensar Technologies has appointed Price Waterhouse Chartered Accountants LLP as its Statutory Auditor for a five-year term starting April 1, 2027. The appointment was approved during the board meeting held on April 24, 2026, ensuring long-term continuity in the company's audit processes.
Zensar Technologies Limited has appointed M/s. Price Waterhouse Chartered Accountants LLP as its new Statutory Auditor. The appointment is for a five-year term effective April 1, 2027. This follows a Board meeting outcome to ensure robust financial governance and statutory compliance.
Zensar Technologies Limited's board has recommended a final dividend of ₹12.6 per equity share for the financial year 2025-26. The dividend is subject to shareholder approval, and the company will intimate book closure and AGM dates separately. This announcement reflects the company's commitment to returning capital to shareholders.
Zensar Technologies reported FY26 revenue of $643.7M, representing 3.1% YoY growth. The company achieved its strongest ever cash position of $319.5M and closed the largest deal in its history during Q4. AI-native offerings gained momentum with 85% of the workforce now AI-certified, driving resilient profitability with a PAT margin of 14.4% in Q4.